Dec 29, 2024, 08:47
Akhil Santhosh: Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-NSCLC
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA) -l
– 24%mpr, 0%pcr
– Again, a different study showing that neoadj osi alone is not the way to go forward …waiting eagerly for neoadaura.”
Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA)
Authors: Jii Bum Lee et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 29, 2024, 08:34
Dec 29, 2024, 07:46
Dec 29, 2024, 00:50
Dec 28, 2024, 18:47
Dec 28, 2024, 18:43
Dec 28, 2024, 18:21
Dec 28, 2024, 18:21
Dec 28, 2024, 18:19